LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants JJ Pellegrino – Chief Financial Officer George LeMaitre – Chairman and Chief Executive Officer Dave Roberts – President Conference Call Participants Brooks O’Neil – Lake Street Scott Henry – Roth Capital Zachary Weiner – Jefferies Javier Fonseca – Spartan Capital Operator Welcome to the LeMaitre Vascular Q4 2021 Financial Results Conference Call. As a reminder, today’s call is being reco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10- Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-282545 ...

LeMaitre Vascular, Inc. Investor Presentation 1 Disclaimers Unaudited Quarterly Results This document contains quarterly financial results. Quarterly financial results are unaudited. Forward-Looking Statements This document contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events described in forward-looking statements. Factors ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q3 2021 Earnings Conference Call October 28, 2021 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer Dave Roberts - President Conference Call Participants Zachary Weiner - Jefferies Rick Wise - Stifel Javier Fonseca - Spartan Capital Brooks O’Neil - Lake Street Capital Mike Petusky - Barrington Research Scott Henry - ROTH Capital Anthony Petrone - Jefferies Operator Welcome to the LeMaitre Vas ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10- Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State o ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2021 Results Conference Call July 29, 2021 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer Dave Roberts - President Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Capital Markets Michael Petusky - Barrington Research Operator Welcome to the LeMaitre Vascular Q2 2021 Financial Results Conference Call. As a reminder, today’s call is being recorded. At this time, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10- Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Delaware 04-2825458 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 63 Second Avenue, Burlington, Massachusetts 01803 (Address of principal executive offices) (Zip Code) (781) 221-2266 (Registrant's telephone num ...

Financial Data and Key Metrics Changes - The company reported Q1 2021 sales of $35.9 million, representing a 17% year-over-year increase [13] - Operating income for Q1 was $7.9 million, an increase of 83% compared to the previous year [17] - EBITDA for Q1 was $10.5 million, with EPS of $0.28, both metrics showing an 83% improvement year-over-year [13][17] Business Line Data and Key Metrics Changes - Artegraft is projected to generate $24 million in sales for the year, reflecting a 29% growth from $18.6 million in the prior year [11] - Artegraft contributed approximately $3 million to Q1 operating income, equating to $0.09 per share [11] - Other biologic projects, including XenoSure and RestoreFlow, are expected to add $1 million and $500,000 in sales respectively for 2021 [12] Market Data and Key Metrics Changes - Sales in the Americas increased by 29%, while AsiaPac sales rose by 25%, but European sales declined by 5% [13][15] - The U.S. market was a significant driver of growth, largely due to Artegraft sales [15] Company Strategy and Development Direction - The company is focused on rebuilding its sales force, with 14 open hiring requisitions as of March 31 [9] - Expansion of warehouse facilities in multiple international locations is planned to enhance customer connections and order fulfillment [10] - The company is actively pursuing acquisitions, particularly in disposables and implantables used by vascular surgeons [39][40] Management's Comments on Operating Environment and Future Outlook - Management noted that COVID-19 continues to impact operations, particularly in Europe, but expects improvements as vaccination rates increase [8][26] - The company anticipates a sales guidance for Q2 2021 between $37 million and $40 million, representing a 55% increase year-over-year [20] - Management expressed confidence in overcoming CE mark challenges, which have been a significant headwind [24][41] Other Important Information - The company ended Q1 2021 with $32 million in total debt, having paid down $7 million during the quarter [17] - Cash reserves decreased by $3.2 million, primarily due to debt repayment, but increased by $3.8 million when excluding this repayment [17] Q&A Session Summary Question: What were the headwinds in Q1 that prevented reaching the upper end of guidance? - Management identified three main issues: CE mark delays, ongoing COVID impacts, and channel loading effects from the previous quarter [24][25] Question: How should investors view the go-forward run rate for Artegraft? - Management confirmed a projected $24 million in sales for Artegraft, with a significant price increase contributing to this growth [28][31] Question: What is the expected ramp-up time for new sales reps? - New U.S. sales reps are expected to take about six months to ramp up, while international reps may take longer due to hiring processes [46][47] Question: How is the macro environment in Europe progressing? - Management refrained from providing specific insights into the macro environment for Q2, preferring to focus on Q1 results [42] Question: What are the costs associated with obtaining CE marks? - Management indicated that the costs are significant but did not provide a specific figure, noting that it is included in R&D expenses [61][63] Question: What is the performance of XenoSure in Q1? - XenoSure sales were down approximately 5% in Q1, with expectations for recovery as CE mark issues are resolved [68]

Financial Performance & Growth - LeMaitre's annual sales have shown growth, as indicated by the provided sales figures[5] - The company's 5-year Compound Annual Growth Rate (CAGR) from 2015-2020 was 11%[7] - LeMaitre's 5-year CAGR for operating income from 2015-2020 was 20%[9] - Q1 2021 sales showed a shift in sales mix toward biologic implants, representing 48% of total sales[15] Market & Strategy - LeMaitre focuses on vascular surgeons, with 82% of sales attributed to this specialist group[11] - The company estimates that over 50% of the 17,000 vascular surgeons worldwide use LeMaitre products[11] - LeMaitre has a 1 or 2 market share position in 11 of 16 markets[12, 13] Global Reach & Approvals - LeMaitre has a worldwide sales reach with direct sales in 24 countries, supported by 86 sales representatives and 11 offices[16] - 95% of Q1 2021 worldwide sales are from products with regulatory approvals in the US market[17] Acquisitions & R&D - LeMaitre has a history of acquisitions, with 24 acquisitions in 23 years[20] - The company has a R&D launch record of 15 wins, 7 losses, and 3 ties or TBD[19] Financial Health - The company maintains a high gross margin, ranging from 50% to nearly 75% between 2016 and H1 2021[23] - LeMaitre has a track record of 10 consecutive years of dividend increases, with a 10-year CAGR of 21% from 2011 to 2021 (estimated)[28]

SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...